Olema Oncology (also known as Olema Pharmaceuticals) is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers. Its lead program, OP-1250, a potential complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
|HQ||San Francisco, CA, US||Map|
Net income (FY, 2019)
EBIT (FY, 2019)
Market capitalization (19-Oct-2021)
Closing stock price (19-Oct-2021)
Olema Oncology has 162 Twitter Followers. The number of followers has increased 2.4% month over month and increased 4.7% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Olema Oncology founded?
Olema Oncology was founded in 2007.
Who are Olema Oncology key executives?
Olema Oncology's key executives are Sean P. Bohen, Cyrus Harmon and Pamela M. Klein.
How many employees does Olema Oncology have?
Olema Oncology has 21 employees.
Who are Olema Oncology competitors?
Competitors of Olema Oncology include PharmaCyte Biotech, OncBioMune Pharmaceuticals and Briacell.
Where is Olema Oncology headquarters?
Olema Oncology headquarters is located at 665 3rd St #250, San Francisco, San Francisco.
Where are Olema Oncology offices?
Olema Oncology has an office in San Francisco.
How many offices does Olema Oncology have?
Olema Oncology has 2 offices.
Receive alerts for 300+ data fields across thousands of companies